(READ) Yet another Covid-19 vaccine to hit the US market

The Centers for Disease Control (CDC) has put its stamp of approval on another Covid-19 vaccine for use in the US: one made by Novavax.

That’s despite the fact that scientists say the Covid vaccines have proved stunningly disappointing in terms of preventing infection or spread of Covid. Originally, the government and vaccine makers claimed the vaccines would prevent infection. When it was learned the vaccines did not prevent infection, the government and vaccine makes claimed they would prevent transmission. When it was learned they did not prevent transmission, the government and vaccine makers claimed that those who have been vaccinated would not get ill. When it was learned they did get ill, the government and vaccine makers claimed vaccinated people would not get seriously ill and become hospitalized. When it was learned they did get seriously ill and become hospitalized, the government and vaccine makers claimed vaccinated people would not die. When they did die, the government and vaccine makers said vaccinated people are more likely to suffer non-serious illness when they get Covid. However, studies show Covid is sickening more people who are vaccinated than not. And CDC says most cases of Covid in people who are unvaccinated, as well as vaccinated, are non-serious.

Today, many vaccine supporters falsely claim the vaccines were never intended to, or designed to, prevent infection.

CDC did not explain how it justifies allowing a less-tested (in the US) vaccine on the US market when there are several vaccines with a more robust history. Typically, in a non-emergency, new drugs aren’t allowed to market if they are less effective than drugs already being used, or if they aren’t proven as safe.

As adverse events related to Covid vaccines– such as serious blood clots, paralysis, and heart damage– have become more understood, the government has had to modify its recommendations and add warnings to the labels. In addition, the government backed off its original recommendation for Johnson and Johnson’s vaccine, limiting its use, due to side effects. The government insists that the serious side effects possible with all of the vaccines on the market are outweighed by their potential benefits.

Those benefit claims are subject to a great deal of scientific debate. Many independent scientists say Covid vaccines provide more risk than benefit.

Read more from CDC:

CDC Recommends Novavax’s COVID-19 Vaccine for Adults  

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation that Novavax’s COVID-19 vaccine be used as another primary series option for adults ages 18 years and older. Novavax’s COVID-19 vaccine, which will be available in the coming weeks, is an important tool in the pandemic and provides a more familiar type of COVID-19 vaccine technology for adults. Having multiple types of vaccines offers more options and flexibility for the public, jurisdictions, and vaccine providers.  

Protein subunit vaccines package harmless proteins of the COVID-19 virus alongside another ingredient called an adjuvant that helps the immune system respond to the virus in the future. Vaccines using protein subunits have been used for more than 30 years in the United States, beginning with the first licensed hepatitis B vaccine. Other protein subunit vaccines used in the United States today include those to protect against influenza and whooping cough (acellular pertussis).  

The following is attributable to Dr. Walensky:  

“Today, we have expanded the options available to adults in the U.S. by recommending another safe and effective COVID-19 vaccine. If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, now is the time to join the millions of Americans who have been vaccinated. With COVID-19 cases on the rise again across parts of the country, vaccination is critical to help protect against the complications of severe COVID-19 disease.”  

Leave a Comment

Your email address will not be published. Required fields are marked *

5 thoughts on “(READ) Yet another Covid-19 vaccine to hit the US market”

  1. This is actually a vaccine and not a therapeutic. CDC dragged its feet on this approval because they favored the new technology, which was doomed to fail. Look at the history of the Covid 229e vaccines as history tends to repeat itself!

Scroll to Top